Denali Advisors LLC Trims Holdings in Cabot Corporation $CBT

Denali Advisors LLC reduced its stake in Cabot Corporation (NYSE:CBT) by 18.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 86,707 shares of the specialty chemicals company’s stock after selling 20,212 shares during the quarter. Denali Advisors LLC owned 0.17% of Cabot worth $7,875,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Torren Management LLC purchased a new stake in Cabot in the fourth quarter valued at approximately $26,000. Rothschild Investment LLC boosted its position in shares of Cabot by 170.4% during the fourth quarter. Rothschild Investment LLC now owns 411 shares of the specialty chemicals company’s stock worth $27,000 after buying an additional 259 shares during the period. Global Retirement Partners LLC grew its stake in shares of Cabot by 1,606.9% in the fourth quarter. Global Retirement Partners LLC now owns 495 shares of the specialty chemicals company’s stock valued at $33,000 after buying an additional 466 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in shares of Cabot by 409.0% in the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock valued at $38,000 after buying an additional 364 shares in the last quarter. Finally, Danske Bank A S purchased a new stake in shares of Cabot in the 3rd quarter valued at $38,000. Hedge funds and other institutional investors own 93.18% of the company’s stock.

Insider Activity at Cabot

In other news, CEO Sean D. Keohane sold 91,923 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $86.41, for a total value of $7,943,066.43. Following the sale, the chief executive officer directly owned 404,134 shares in the company, valued at approximately $34,921,218.94. This trade represents a 18.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.08% of the company’s stock.

Cabot Stock Performance

Shares of CBT opened at $85.34 on Thursday. Cabot Corporation has a 1 year low of $58.33 and a 1 year high of $94.53. The stock has a market capitalization of $4.41 billion, a PE ratio of 24.04, a PEG ratio of 10.99 and a beta of 0.84. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.97 and a current ratio of 1.47. The stock has a 50-day simple moving average of $88.23 and a 200-day simple moving average of $80.75.

Cabot (NYSE:CBT) last released its earnings results on Monday, August 3rd. The specialty chemicals company reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.66 by $0.01. The firm had revenue of $982.00 million for the quarter, compared to analyst estimates of $943.16 million. Cabot had a net margin of 5.23% and a return on equity of 20.29%. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.90 earnings per share. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. On average, analysts predict that Cabot Corporation will post 6.33 earnings per share for the current fiscal year.

Cabot Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be given a $0.4725 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.89 dividend on an annualized basis and a dividend yield of 2.2%. Cabot’s dividend payout ratio is currently 53.24%.

Analyst Upgrades and Downgrades

CBT has been the topic of several research reports. JPMorgan Chase & Co. increased their target price on Cabot from $70.00 to $78.00 and gave the stock an “underweight” rating in a research note on Friday, August 7th. UBS Group dropped their target price on Cabot from $97.00 to $92.00 and set a “neutral” rating for the company in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Cabot from a “hold” rating to a “buy” rating in a research report on Sunday, August 9th. Mizuho raised their price objective on shares of Cabot from $80.00 to $90.00 and gave the company a “neutral” rating in a research note on Thursday, June 25th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Cabot in a report on Tuesday, May 26th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Cabot has an average rating of “Hold” and a consensus price target of $89.00.

Cabot Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.